CEL-SCI Reports September Patient Enrollment for Its Phase 3 Head and Neck Cancer Trial

By: via Benzinga
CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that in the month of September it has enrolled 30 ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.